Ledipasvir/Sofosbuvir is Effective for Relapsed Genotype 1b Hepatitis C Virus Patients after Achieving a Sustained Virological Response at Post-treatment Week 12 with Glecaprevir/Pibrentasvir-Reference-Cited by-同舟云学术

Ledipasvir/Sofosbuvir is Effective for Relapsed Genotype 1b Hepatitis C Virus Patients after Achieving a Sustained Virological Response at Post-treatment Week 12 with Glecaprevir/Pibrentasvir

Published:2023 Issue: Volume: Page:
ISSN:0918-2918
Container-title:Internal Medicine
language:en
Short-container-title:Intern. Med.

Author:

Manabe Takushi¹,Tadokoro Tomoko¹,Nakahara Mai¹,Ohura Kyoko¹,Fujita Koji¹,Tani Joji¹,Morishita Asahiro¹,Ogawa Chikara²,Masaki Tsutomu¹

Affiliation:

1. Department of Gastroenterology and Neurology, Faculty of Medicine, Kagawa University, Japan

2. Department of Gastroenterology and Hepatology, Takamatsu Red Cross Hospital, Japan

Publisher

Japanese Society of Internal Medicine

Subject

General Medicine,Internal Medicine

Link

https://www.jstage.jst.go.jp/article/internalmedicine/advpub/0/advpub_0865-22/_pdf

Reference21 articles.

1. 1. Kiyosawa K, Sodeyama T, Tanaka E, et al. Interrelationship of blood transfusion, non-A, non-B hepatitis and hepatocellular carcinoma: analysis by detection of antibody to hepatitis C virus. Hepatology 12: 671-675, 1990.

2. 2. Nagata H, Nakagawa M, Asahina Y, et al. Effect of interferon-based and -free therapy on early occurrence and recurrence of hepatocellular carcinoma in chronic hepatitis C. J Hepatol 67: 933-939, 2017.

3. 3. Kanda T, Yasui S, Nakamura M, et al. Real-world experiences with the combination treatment of ledipasvir plus sofosbuvir for 12 weeks in HCV genotype 1-infected Japanese patients: achievement of a sustained virological response in previous users of peginterferon plus ribavirin with HCV NS3/4A inhibitors. Int J Mol Sci 18: 906, 2017.

4. 4. Iio E, Shimada N, Takaguchi K, et al. Clinical evaluation of sofosbuvir/ledipasvir in patients with chronic hepatitis C genotype 1 with and without prior daclatasvir/asunaprevir therapy. Hepatol Res 47: 1308-1316, 2017.

5. 5. Ng TI, Krishnan P, Pilot-Matias T, et al. In vitro antiviral activity and resistance profile of the next generation hepatitis C virus NS5A inhibitor pibrentasvir. Antimicrob Agents Chemother 61: e02558, 2017.